Differential WNT gene expression in various subtypes of acute lymphoblastic leukemia

Iranian Journal of Immunology

Volumn 9, Issue 1, 2012, Pages 61-71

  Memarian, Al ^a   Vosough, Parvaneh ^b   Asgarian Omran, Hossein ^a   Tabrizi, Mina ^c   Shabani, Mahdi ^d   Shokri, Fazel ^a,d  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b IRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d AVICENNA RESEARCH INSTITUTE   (Iran)

Author keywords

Acute lymphoblastic leukemia; Immunophenotype; RT PCR; WNT

Indexed keywords

WNT PROTEIN; WNT10A PROTEIN; WNT11 PROTEIN; WNT5B PROTEIN; WNT7A PROTEIN; WNT7B PROTEIN; WNT9A PROTEIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; CHILD; CONTROLLED STUDY; DOWN REGULATION; GENE; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; INFANT; LEUKEMIA CELL; LEUKEMOGENESIS; MAJOR CLINICAL STUDY; PERIPHERAL BLOOD MONONUCLEAR CELL; PRESCHOOL CHILD; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCHOOL CHILD; WNT 10A GENE; WNT 11 GENE; WNT 16B GENE; WNT 2B GENE; WNT 5A GENE; WNT 5B GENE; WNT 7A GENE; WNT 7B GENE; WNT 9A GENE; WNT GENE;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; IMMUNOPHENOTYPING; INFANT; PRECURSOR B-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PRECURSOR T-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROTEIN ISOFORMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSCRIPTOME; WNT PROTEINS; YOUNG ADULT;

EID: 84861697708     PISSN: 17351383     EISSN: 1735367X     Source Type: Journal    
DOI: None     Document Type: Article

References (62)

1. Pui CH, Evans WE. Acute lymphoblastic leukemia. The New England journal of medicine. 1998; 339:605-615.
2. Brincker H. Population-based age- and sex-specific incidence rates in the 4 main types of leukaemia. Scandinavian journal of haematology. 1982; 29:241-249.
3. Pui CH, Relling MV, Downing JR. Acute lymphoblastic leukemia. The New England journal of medicine. 2004; 350:1535-1548.
4. Cortes JE, Kantarjian HM. Acute lymphoblastic leukemia. A comprehensive review with emphasis on biology and therapy. Cancer. 1995; 76:2393-2417.
5. Johansson B, Mertens F, Mitelman F. Clinical and biological importance of cytogenetic abnormalities in childhood and adult acute lymphoblastic leukemia. Annals of medicine. 2004; 36:492-503.
6. Staal FJ, Luis TC, Tiemessen MM. WNT signalling in the immune system: WNT is spreading its wings. Nat Rev Immunol. 2008; 8:581-593.
7. Chen X, Yang J, Evans PM, Liu C. Wnt signaling: the good and the bad. Acta biochimica et biophysica Sinica. 2008; 40:577-594.
8. Kokolus K, Nemeth MJ. Non-canonical Wnt signaling pathways in hematopoiesis. Immunologic research. 2010; 46:155-164.
9. Weerkamp F, van Dongen JJ, Staal FJ. Notch and Wnt signaling in T-lymphocyte development and acute lymphoblastic leukemia. Leukemia. 2006; 20:1197-1205.
10. Arce L, Yokoyama NN, Waterman ML. Diversity of LEF/TCF action in development and disease. Oncogene. 2006; 25:7492-7504.
11. Polakis P. The many ways of Wnt in cancer. Current opinion in genetics & development. 2007; 17:45-51.
12. Liang H, Chen Q, Coles AH, Anderson SJ, Pihan G, Bradley A, et al. Wnt5a inhibits B cell proliferation and functions as a tumor suppressor in hematopoietic tissue. Cancer cell. 2003; 4:349-360.
13. Mikels AJ, Nusse R. Purified Wnt5a protein activates or inhibits beta-catenin-TCF signaling depending on receptor context. PLoS biology. 2006; 4:e115.
14. Liang H, Coles AH, Zhu Z, Zayas J, Jurecic R, Kang J, et al. Noncanonical Wnt signaling promotes apoptosis in thymocyte development. The Journal of experimental medicine. 2007; 204:3077-3084.
15. Khan NI, Bendall LJ. Role of WNT signaling in normal and malignant hematopoiesis. Histology and histopathology. 2006; 21:761-774.
16. Ewan KB, Dale TC. The potential for targeting oncogenic WNT/beta-catenin signaling in therapy. Current drug targets. 2008; 9:532-547.
17. Ge X, Wang X. Role of Wnt canonical pathway in hematological malignancies. Journal of hematology & oncology. 2010; 3:33.
18. Roman-Gomez J, Cordeu L, Agirre X, Jimenez-Velasco A, San Jose-Eneriz E, Garate L, et al. Epigenetic regulation of Wnt-signaling pathway in acute lymphoblastic leukemia. Blood. 2007; 109:3462-3469.
19. Khan NI, Bradstock KF, Bendall LJ. Activation of Wnt/beta-catenin pathway mediates growth and survival in B-cell progenitor acute lymphoblastic leukaemia. Br J Haematol. 2007; 138:338-348.
20. Martin V, Agirre X, Jimenez-Velasco A, Jose-Eneriz ES, Cordeu L, Garate L, et al. Methylation status of Wnt signaling pathway genes affects the clinical outcome of Philadelphia-positive acute lymphoblastic leukemia. Cancer Sci. 2008; 99:1865-1868.
21. Deng G, Li ZQ, Zhao C, Yuan Y, Niu CC, Zhao C, et al. WNT5A expression is regulated by the status of its promoter me-thylation in leukaemia and can inhibit leukemic cell malignant proliferation. Oncology reports. 2011; 25:367-376.
22. Gharagozlou S, Kardar GA, Rabbani H, Shokri F. Molecular analysis of the heavy chain variable region genes of human hybridoma clones specific for coagulation factor VIII. Thrombosis and haemostasis. 2005; 94:1131-1137.
23. Asgarian Omran H, Shabani M, Shahrestani T, Sarafnejad A, Khoshnoodi J, Vossough P, et al. Immunophenotypic subtyp-ing of leukemic cells from Iranian patients with acute lymphoblastic leukaemia: association to disease outcome. Iran J Immunol. 2007; 4:15-25.
24. Kazemi T, Asgarian-Omran H, Hojjat-Farsangi M, Shabani M, Memarian A, Sharifian RA, et al. Fc receptor-like 1-5 molecules are similarly expressed in progressive and indolent clinical subtypes of B-cell chronic lymphocytic leukemia. Int J Cancer. 2008; 123:2113-2119.
25. Memarian A, Jeddi Tehrani M, Vossough P, Sharifian RA, Rabbani H, Shokri F. Expression profile of Wnt molecules in leukemic cells from Iranian patients with acute myeloblastic leukemia. Iran J Immunol. 2007; 4:145-154.
26. Dosen G, Tenstad E, Nygren MK, Stubberud H, Funderud S, Rian E. Wnt expression and canonical Wnt signaling in human bone marrow B lymphopoiesis. BMC immunology. 2006; 7:13.
27. Malhotra S, Kincade PW. Wnt-related molecules and signaling pathway equilibrium in hematopoiesis. Cell stem cell. 2009; 4:27-36.
28. Staal FJ, Luis TC. Wnt signaling in hematopoiesis: crucial factors for self-renewal, proliferation, and cell fate decisions. J Cell Biochem. 2010; 109:844-849.
29. Giles RH, van Es JH, Clevers H. Caught up in a Wnt storm: Wnt signaling in cancer. Biochimica et biophysica acta. 2003; 1653:1-24.
30. Reya T, Clevers H. Wnt signalling in stem cells and cancer. Nature. 2005; 434:843-50.
31. Gandhirajan RK, Poll-Wolbeck SJ, Gehrke I, Kreuzer KA. Wnt/beta-catenin/LEF-1 signaling in chronic lymphocytic leukemia (CLL): a target for current and potential therapeutic options. Current cancer drug targets. 2010; 10:716-727.
32. Fu Y, Zheng S, An N, Athanasopoulos T, Popplewell L, Liang A, et al. beta-catenin as a potential key target for tumor suppression. Int J Cancer. 2011; 129:1541-1551.
33. Roman-Gomez J, Jimenez-Velasco A, Agirre X, Castillejo JA, Navarro G, Barrios M, et al. Transcriptional silencing of the Dickkopfs-3 (Dkk-3) gene by CpG hypermethylation in acute lymphoblastic leukaemia. British journal of cancer. 2004; 91:707-713.
34. Valencia A, Roman-Gomez J, Cervera J, Such E, Barragan E, Bolufer P, et al. Wnt signaling pathway is epigenetically regulated by methylation of Wnt antagonists in acute myeloid leukemia. Leukemia. 2009; 23:1658-1666.
35. Mazieres J, You L, He B, Xu Z, Lee AY, Mikami I, et al. Inhibition of Wnt16 in human acute lymphoblastoid leukemia cells containing the t(1;19) translocation induces apoptosis. Oncogene. 2005; 24:5396-5400.
36. McWhirter JR, Neuteboom ST, Wancewicz EV, Monia BP, Downing JR, Murre C. Oncogenic homeodomain transcription factor E2A-Pbx1 activates a novel WNT gene in pre-B acute lymphoblastoid leukemia. Proceedings of the National Academy of Sciences of the United States of America. 1999; 96:11464-11469.
37. Roman-Gomez J, Jimenez-Velasco A, Cordeu L, Vilas-Zornoza A, San Jose-Eneriz E, Garate L, et al. WNT5A, a putative tumour suppressor of lymphoid malignancies, is inactivated by aberrant methylation in acute lymphoblastic leukaemia. Eur J Cancer. 2007; 43:2736-2746.
38. Omran HA, Shabani M, Vossough P, Sharifian R, Tabrizi M, Khoshnoodi J, et al. Cross-sectional monitoring of Wilms' tumor gene 1 (WT1) expression in Iranian patients with acute lymphoblastic leukemia at diagnosis, relapse and remission. Leuk Lymphoma. 2008; 49:281-290.
39. Mikaelsson E, Danesh-Manesh AH, Luppert A, Jeddi-Tehrani M, Rezvany MR, Sharifian RA, et al. Fibromodulin, an extracellular matrix protein: characterization of its unique gene and protein expression in B-cell chronic lymphocytic leukemia and mantle cell lymphoma. Blood. 2005; 105:4828-4835.
40. Shabani M, Asgarian-Omran H, Jeddi-Tehrani M, Vossough P, Faranoush M, Sharifian RA, et al. Overexpression of orphan receptor tyrosine kinase Ror1 as a putative tumor-associated antigen in Iranian patients with acute lymphoblastic leukemia. Tumour Biol. 2007; 28:318-326.
41. Katoh M. WNT/PCP signaling pathway and human cancer (review). Oncology reports. 2005; 14:1583-1588.
42. Golan T, Yaniv A, Bafico A, Liu G, Gazit A. The human Frizzled 6 (HFz6) acts as a negative regulator of the canonical Wnt. beta-catenin signaling cascade. J Biol Chem. 2004; 279:14879-14888.
43. Maye P, Zheng J, Li L, Wu D. Multiple mechanisms for Wnt11-mediated repression of the canonical Wnt signaling pathway. J Biol Chem. 2004; 279:24659-24665.
44. Ying J, Li H, Chen YW, Srivastava G, Gao Z, Tao Q. WNT5A is epigenetically silenced in hematologic malignancies and inhibits leukemia cell growth as a tumor suppressor. Blood. 2007; 110:4130-4132.
45. Sercan HO, Pehlivan M, Simsek O, Ates H, Sercan Z. Induction of apoptosis increases expression of non-canonical WNT genes in myeloid leukemia cell lines. Oncology reports. 2007; 18:1563-1569.
46. Zhu H, Mazor M, Kawano Y, Walker MM, Leung HY, Armstrong K, et al. Analysis of Wnt gene expression in prostate cancer: mutual inhibition by WNT11 and the androgen receptor. Cancer research. 2004; 64:7918-7926.
47. Yuan Y, Niu CC, Deng G, Li ZQ, Pan J, Zhao C, et al. The Wnt5a/Ror2 noncanonical signaling pathway inhibits canonical Wnt signaling in K562 cells. International journal of molecular medicine. 2011; 27:63-69.
48. Chung EJ, Hwang SG, Nguyen P, Lee S, Kim JS, Kim JW, et al. Regulation of leukemic cell adhesion, proliferation, and survival by beta-catenin. Blood. 2002; 100:982-990.
49. Winn RA, Marek L, Han SY, Rodriguez K, Rodriguez N, Hammond M, et al. Restoration of Wnt-7a expression reverses non-small cell lung cancer cellular transformation through frizzled-9-mediated growth inhibition and promotion of cell differentiation. J Biol Chem. 2005; 280:19625-19634.
50. Katoh M. WNT2B: comparative integromics and clinical applications (Review). International journal of molecular medicine. 2005; 16:1103-1108.
51. Van Den Berg DJ, Sharma AK, Bruno E, Hoffman R. Role of members of the Wnt gene family in human hematopoiesis. Blood. 1998; 92:3189-3202.
52. Kirikoshi H, Sekihara H, Katoh M. Up-regulation of WNT10A by tumor necrosis factor alpha and Helicobacter pylori in gastric cancer. International journal of oncology. 2001; 19:53353-6.
53. Lu D, Zhao Y, Tawatao R, Cottam HB, Sen M, Leoni LM, et al. Activation of the Wnt signaling pathway in chronic lym-phocytic leukemia. Proceedings of the National Academy of Sciences of the United States of America. 2004; 101:3118-3123.
54. Wu QL, Zierold C, Ranheim EA. Dysregulation of Frizzled 6 is a critical component of B-cell leukemogenesis in a mouse model of chronic lymphocytic leukemia. Blood. 2009; 113:3031-3039.
55. Thiago LS, Costa ES, Lopes DV, Otazu IB, Nowill AE, Mendes FA, et al. The Wnt signaling pathway regulates Nalm-16 b-cell precursor acute lymphoblastic leukemic cell line survival and etoposide resistance. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 2010; 64:63-72.
56. Memarian A, Hojjat-Farsangi M, Asgarian-Omran H, Younesi V, Jeddi-Tehrani M, Sharifian RA, et al. Variation in WNT genes expression in different subtypes of chronic lymphocytic leukemia. Leuk Lymphoma. 2009; 50:2061-2070.
57. Qiang YW, Walsh K, Yao L, Kedei N, Blumberg PM, Rubin JS, et al. Wnts induce migration and invasion of myeloma plasma cells. Blood. 2005; 106:1786-1793.
58. Wang Z, Shu W, Lu MM, Morrisey EE. Wnt7b activates canonical signaling in epithelial and vascular smooth muscle cells through interactions with Fzd1, Fzd10, and LRP5. Mol Cell Biol. 2005; 25:5022-5030.
59. Person AD, Garriock RJ, Krieg PA, Runyan RB, Klewer SE. Frzb modulates Wnt-9a-mediated beta-catenin signaling during avian atrioventricular cardiac cushion development. Dev Biol. 2005; 278:35-48.
60. Casagrande G, te Kronnie G, Basso G. The effects of siRNA-mediated inhibition of E2A-PBX1 on EB-1 and Wnt16b expression in the 697 pre-B leukemia cell line. Haematologica. 2006; 91:765-771.
61. Sallan SE, Ritz J, Pesando J, Gelber R, O'Brien C, Hitchcock S, et al. Cell surface antigens: prognostic implications in childhood acute lymphoblastic leukemia. Blood. 1980; 55:395-402.
62. Mochmann LH, Bock J, Ortiz-Tanchez J, Schlee C, Bohne A, Neumann K, et al. Genome-wide screen reveals WNT11, a non-canonical WNT gene, as a direct target of ETS transcription factor ERG. Oncogene. 2011; 30:2044-2056.